Showing 12 posts of 12 posts found.


Novo Nordisk’s Wegovy reduces risk of cardiovascular events

August 9, 2023
Research and Development Cardiology, Novo Nordisk, Wegovy, cardiovascular, cvd, semaglutide

Novo Nordisk has shared results from the SELECT cardiovascular outcomes trial, which show that a once weekly subcutaneous dose of …

Evox Therapeutics enters agreement for next generation gene therapy for heart disease

August 4, 2023
Research and Development Cardiology, Evox Therapeutics, Icahn Mount Sinai, cvd, gene therapy

Evox Therapeutics has announced a research collaboration and option agreement with the Icahn School of Medicine at Mount Sinai (Icahn …

Ionis and Novartis partner for CVD treatment programme

August 4, 2023
Business Services Cardiology, Ionis Pharmaceuticals, License Agreement, Novartis, cvd

Ionis Pharmaceuticals has announced that it has entered into a new collaboration and license agreement with Novartis, aiming to discover, …

American Heart Association awards $2.1m to research link between migraine, strokes and CVD

July 27, 2023
Research and Development American Heart Association, Cardiology, cvd, migraine, stroke

The American Heart Association has announced that it will fund seven new scientific research studies to learn more about the …

AstraZeneca’s Farxiga approved to reduce risk of cardiovascular death

May 9, 2023
Medical Communications AstraZeneca, Cardiology, FDA, cvd, farxiga, heart failure

AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved Farxiga to reduce the risk of cardiovascular …


Significant lack of women and minorities involved in clinical trials for cardiometabolic medication, research shows

June 1, 2020
Sales and Marketing cardio, cardiovascular, cvd

Women and minorities, particularly African Americans, continue to be under represented in clinical trials for cardiometabolic medication, according to a …

Positive CHMP recommendation for Sanofi’s atherosclerotic CVD drug Praluent

February 4, 2019
Sales and Marketing Europe, atherosclerotic cardiovascular disease, cvd, pharma, praluent

It has been announced that Sanofi’s Praluent (alirocumab) has been awarded a positive recommendation from the European Medicines Agency’s Committee …


The new and improved Spring 2018 edition of Pharmafile is available to read online now!

May 9, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CNS, Cancer, Pharmafocus, cardiovascular, cvd, oncology, pharmafile

The Spring 2018 edition of Pharmafile, our long-running bi-annual guide to the latest trends, projections and thought leadership positions in …


Eli Lilly partners with Chinese institution to advance the nation’s diabetes and CVD care

April 27, 2018
Medical Communications, Research and Development China, Eli Lilly, cardiovascular disorders, cvd, diabetes, pharma, type 2 diabetes

EIi Lilly has announced plans to partner up with China’s National Center for Cardiovascular Diseases (NCCD), the nation’s institution responsible …

ESC congress sign

NHS looks to ESC for next-gen heart drug data

August 28, 2015
Medical Communications, Research and Development ALN-PCScs, Repatha, alirocumab, cardiology, cardiovascular disease, cvd, evolocumab, heart disease, high cholesterol, praluent

New data is expected to be presented at the European Cardiology Society congress in London, on the high cholesterol drugs …

BMS image

BMS enters gene therapy development deal

April 7, 2015
Research and Development BMS, Bristol-Myers Squibb, R&D, cardiovascular disease, cvd, heart disease, heart failure, uniQure

Bristol-Myers Squibb (BMS) has signed a multi-million dollar agreement with Amsterdam-based gene therapy firm uniQure to boost research into new …

NICE image

NICE: ‘Use more statins’

February 12, 2014
Sales and Marketing NHS, NICE, baker, cvd, statins

NICE has decided more NHS patients ought to be considered at risk of cardiovascular disease (CVD) – and therefore advises …

Latest content